论文部分内容阅读
目的 观察吡柔比星经动脉灌注化疗栓塞 (TACE)在治疗原发性肝癌 (HCC)中的疗效及不良反应。方法 收集经病理确诊为HCC 2 1例 ,采用以吡柔比星 (THP)为主的联合化疗方案经动脉插管行 2～ 6次灌注化疗栓塞 ,进行疗效与毒副反应观察对比。结果 总有效率 42 .9% ;毒副反应为Ⅰ～Ⅲ度 ,白细胞降低 9例 ( 4 2 .6 % ) ,血小板减少 4例( 19% ) ,恶心、呕吐 10例 ( 4 7.6 % ) ,肝功能指标较化疗前升高 11例 ( 5 2 .4% ) ,心电图—过性ST段改变 2例 ( 9.5 % ) ,脱发 1例 ( 4 .7% )。结论 以吡柔比星为主的联合化疗方案治疗HCC疗效较好 ,毒副反应较低。
Objective To observe the efficacy and adverse reactions of pirarubicin via arterial infusion chemoembolization (TACE) in the treatment of primary hepatocellular carcinoma (HCC). Methods Totally 1 case was diagnosed as HCC by pathology. The patients were treated with THP-based combination chemotherapy with arterial intubation for 2 to 6 times. The curative effect and toxicity were observed and compared. Results The total effective rate was 42.9%; the toxicity was grade Ⅰ ~ Ⅲ, leukopenia in 9 cases (42.6%), thrombocytopenia in 4 cases (19%), nausea and vomiting in 10 cases (7.6% Elevated hepatic function was found in 11 cases (5.24%) before chemotherapy, electrocardiogram-transient ST segment changes in 2 cases (9.5%) and hair loss in 1 case (4.7%). Conclusion The combination of pirarubicin-based chemotherapy in the treatment of HCC better efficacy, low toxicity.